Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two pa ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...

VNRX READ THE FULL VNRX RESEARCH REPORT RECENT EVENTS Nu.Q Discover to be Utilized in a Human Clinical Study On March 4, 2025 ...

OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...

Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...

Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.A recent comprehensive analysis of the Chronic ...

Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

Income tax expense increased by $6.7 million in 2024 compared to 2023, primarily due to an increase in U.S. taxes under the ...

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Cullinan Therapeutics to post earnings ...